Page 262 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
Figure 1. Survival curves from end of induction 1 of the patients with RUNX1::RUNX1T1-positive acute myeloid leukemia in the AML-12 cohort. (A) Event-free survival (EFS) according to KIT exon 17 mutational status. The 5-year EFS was 77.2% (95% confi- dence interval [CI]: 64.0-86.1) and 40.0% (95% CI: 21.3-58.1%) in patients without and with KIT exon 17 mutations, respectively (P< 0.001). (B) Overall survival (OS) according to KIT exon 17 mutational status. The 5-year OS was 90.7% (95% CI: 79.1-96.1) and 59.5% (95% CI: 37.8-75.8) in patients without and with KIT exon 17 mutations, respectively (P<0.001). (C) EFS according to flow cytom- etry-measurable residual disease (flow-MRD) levels at end of induction 1 (EOI1). The 5-year EFS was 71.6% (95% CI: 59.9-80.5) and 12.5% (95% CI: 0.7-42.3) in patients with negative and positive MRD at EOI1, respectively (P<0.001). (D) OS according to flow- MRD levels at EOI1. The 5-year OS was 85.9% (95% CI: 75.2-92.2) and 37.5% (95% CI: 8.7-67.4) in patients with negative and pos- itive MRD at EOI1, respectively (P<0.001). (E) EFS according to KIT exon 17 mutational status and flow-MRD levels at EOI1. The 5-year EFS was 80.0% (95% CI: 66.8-88.4) in patients without KIT exon 17 mutations and with negative MRD at EOI1, 47.4% (95% CI: 24.4-67.3) in those with the mutations and with negative MRD (P=0.003), 0.0% in those without the mutations and with pos- itive MRD (P<0.001), and 16.7% (95% CI: 0.8-51.7) in those with the mutations and with positive MRD (P<0.001). (F) OS according to KIT exon 17 mutational status and flow-MRD levels at EOI1. The 5-year OS was 92.2% (95% CI: 80.4-97.0) in patients without KIT exon 17 mutations and with negative MRD at EOI1, 68.0% (95% CI: 42.1-84.2) in those with the mutations and with negative MRD (P=0.006), 50.0% (95% CI: 0.6-91.0) in those without the mutations and with positive MRD (P=0.015), and 33.3% (95% CI: 4.6- 67.6) in those with the mutations and with positive MRD (P<0.001). Panels (E and F) present P values compared to patients with- out KIT exon 17 mutations and with negative MRD at EOI1. Ex17: exon 17; WT: wild-type; MT: mutated; neg: negative; pos: positive.
AB
CD
Figure 2. Survival curves of the patients with RUNX1::RUNX1T1-positive acute myloid leukemia in the TARGET cohort. (A) Event- free survival (EFS) according to KIT exon 17 mutational status. The 5-year EFS was 72.1% (95% confidence interval [CI]: 62.0-79.9) and 62.5% (95% CI: 34.9-81.1) in patients without and with KIT exon 17 mutations, respectively (P=0.431). (B) Overall survival (OS) according to KIT exon 17 mutational status. The 5-year OS was 80.0% (95% CI: 70.4-86.8) and 87.1% (95% CI: 57.3-96.6) in patients without and with KIT exon 17 mutations, respectively (P=0.550). (C) EFS according to gemtuzumab ozogamicin (GO) treatment in the patients with KIT exon 17 mutations. The 5-year EFS was 87.5% (95% CI: 38.7-98.1) and 37.5% (95% CI: 8.7-67.4) in patients who were treated and not treated with GO, respectively (P=0.059). (D) EFS according to GO treatment in the patients without KIT exon 17 mutations. The 5-year EFS was 74.9% (95% CI: 60.0-84.9) and 69.4% (95% CI: 54.5-80.3) in patients who were treated and not treated with GO, respectively (P=0.650). Ex17: exon 17; WT: wild-type; MT: mutated.
Haematologica | 110 January 2025
254